Makers Laboratories (BOM:506919) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506919 Makers Laboratories Ltd BOM:506919
67 GF Score
Price ₹190.80
GF Value ₹182.55
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Makers Laboratories SpecialCharges?

Special Charges only applies to banks.

BOM:506919
67GF Score
Makers Laboratories Ltd BOM:506919
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Makers Laboratories (BOM:506919) Overvalued in 2026?

Based on GuruFocus' analysis, Makers Laboratories stock appears to be overvalued. The current stock price of ₹190.80 is trading 4.5% above its estimated GF Value™ of ₹182.55. GuruFocus considers Makers Laboratories to be Fairly Valued.

Key valuation signals for BOM:506919:

  • SpecialCharges:
  • GF Value™: ₹182.55 vs. price of ₹190.80 (4.5% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:506919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Makers Laboratories Business Description

Other Exchanges MAKERSL:India
Address 54-D, Kandivli Industrial Estate, Charkop, Kandivali (West), Mumbai, MH, IND, 400067
Makers Laboratories Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company's product portfolio includes Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough Range), and Exylin (Amoxycillin range), among others. The reportable segment of the company is the Pharmaceutical segment.
67GF Score

Get the complete analysis for BOM:506919

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹190.80
Price
₹182.55
GF Value